• News
  • SAN DIEGO
  • BioTech

Michael Narachi joins PhRMA's board of directors

Orexigen Therapeutics Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced that Michael Narachi, president and CEO, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a two-year term.

PhRMA represents biopharmaceutical research and biotechnology companies that are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.

"PhRMA represents an industry dedicated to the noblest of missions: Improving the health of patients all over the world," Narachi said. "I'm honored to join the board of PhRMA, and I'm looking forward to being a part of an organization whose mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients."

Narachi has served as Orexigen's president and CEO and a member of Orexigen's board of directors since March 2009.

Before joining Orexigen, Narachi served as chairman, CEO and president of Ren Pharmaceuticals Inc., a private biotechnology company, and chairman of the board of directors of Naryx Pharma Inc., a private pharmaceutical company. In 2004, Narachi left Amgen Inc., where he served as an officer and vice president and as general manager of Amgen's anemia business.

Narachi also serves as a member of the board of directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals Inc. (Nasdaq: AMAG), a pharmaceutical company.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
OREX
3.02
  0.19  
+ 6.71%
9,938,773,000
9.37
1.84

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President